Phase I/II Trial Of Sequential Therapy With Cytarabine And Bismuth-213-Labeled HuM195 (Humanized Anti-CD33) In Patients With Advanced Myeloid Malignancies.

Trial Profile

Phase I/II Trial Of Sequential Therapy With Cytarabine And Bismuth-213-Labeled HuM195 (Humanized Anti-CD33) In Patients With Advanced Myeloid Malignancies.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 24 Jun 2014

At a glance

  • Drugs Lintuzumab Bi-213 (Primary) ; Cytarabine; Filgrastim
  • Indications Acute myeloid leukaemia; Anaemia; Chronic myeloid leukaemia
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 05 Jan 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 02 Apr 2008 Status changed from recruiting to in progress, from clinicaltrials.gov record.
    • 01 Apr 2008 The expected completion date for this trial is now 1 Dec 2010, from clinicaltrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top